🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchBimagrumab + semaglutide — myostatin inhibitor combo for body recomp Page 5

Bimagrumab + semaglutide — myostatin inhibitor combo for body recomp

MikeFit_NJ Thu, May 14, 2026 at 9:31 AM 22 replies 751 viewsPage 5 of 5
jason_sac26
New Member
34
123
Jan 2026
Sacramento, CA
May 17, 2026 at 2:30 AM#21
jason_paloalto said:
Agreed, with the usual condition: that holds for the average and this board is a collection of individuals.

Same pattern here, and in the same order. Posting only so the count is not one.

Last edited: May 17, 2026 at 4:30 AM
18 18pete_RVA, CarlaRPh_TPA, steph_laguna and 15 others
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
May 17, 2026 at 7:34 PM#22
jason_paloalto said:
Agreed, with the usual condition: that holds for the average and this board is a collection of individuals.

Adding the part of the answer the thread has not reached. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

Last edited: May 17, 2026 at 10:34 PM
17 17dan_philly, MeganSA_TX, LarryQC_SD and 14 others
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
May 18, 2026 at 12:38 PM#23

Adding the numbers, since they settle part of this. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

16 16LondonLisa, mike_nyc, VendorMark and 13 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
ingrid_STO
Member
345
1,456
Jul 2024
Stockholm, SE
May 19, 2026 at 5:42 AM#24

One thing that is still open after jason_paloalto’s answer:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: May 19, 2026 at 8:42 AM
15 15InsuranceTom, WendyG_ATL, SaraMom3 and 12 others
Reply Quote Save Share Report
LeilaHI
Member
167
789
Jan 2025
Honolulu, HI
May 19, 2026 at 10:45 PM#25
DataDave said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

14 14amsterdam_pete, LondonLisa, mike_nyc and 11 others
Reply Quote Save Share Report
1345

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register